Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2016-03-25 AGM Information
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
160325 - Convening notice GM 28 April 2016_FINAL.pdf
AGM Information Classification · 99% confidence The document is explicitly titled a "CONVENING NOTICE TO ATTEND THE GENERAL MEETING OF SHAREHOLDERS" and details the agenda for both an Ordinary and Extraordinary General Meeting (AGM/EGM) scheduled for April 28, 2016. The agenda items cover the approval of annual accounts, discharge of directors, director appointments/renewals, remuneration report approval, and capital authorization renewal. These are core activities conducted during an Annual General Meeting. Therefore, the document fits the definition of AGM Information.
2016-03-25 English
160325 - Convocation Assemblée Générale 28 avril 2016_FINAL.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "CONVOCATION À L'ASSEMBLÉE GÉNÉRALE DES ACTIONNAIRES" (Notice of General Shareholders' Meeting) and details the agenda for both Ordinary and Extraordinary General Meetings (AGM/EGM) scheduled for April 28, 2016. The agenda items include voting on annual accounts, remuneration reports, director appointments, and capital authorization renewal. This content perfectly matches the definition of materials shared during an Annual General Meeting. The document is a formal notice/agenda for the meeting itself, not just a report publication announcement (RPA) or a general regulatory filing (RNS). Therefore, the most specific classification is AGM-R.
2016-03-25 French
160325 - Oproeping Algemene Vergadering 28 april 2016_FINAL.pdf
AGM Information Classification · 99% confidence The document is explicitly titled "OPROEPING TOT DE ALGEMENE VERGADERING VAN AANDEELHOUDERS" (Notice of the General Meeting of Shareholders) and details the agenda items for both the Ordinary and Extraordinary General Meetings scheduled for April 28, 2016. The agenda includes voting on the annual accounts, remuneration report, director appointments/renewals, and specific corporate governance matters like change of control clauses (related to EMTN Program and EIB Credit Agreement) and authorization for share allocation. These elements are characteristic of materials distributed to shareholders in preparation for an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2016-03-25 Dutch
UCB Exxelerate Cimzia Press Release ENG
Earnings Release Classification · 99% confidence The document is titled with an announcement: "UCB Announces Results from First Head-to-Head study of Cimzia® (certolizumab pegol) and Humira® (adalimumab) in Bio-Naïve Rheumatoid Arthritis Patients". It details the top-line results of a clinical study (EXXELERATE), including efficacy data (ACR20 responses, low disease activity) and safety profiles, comparing two drugs. This structure—announcing key findings immediately followed by detailed context and safety information—is characteristic of an Earnings Release (ER) or a press release announcing clinical trial data. Since the document focuses purely on the announcement of study results and does not appear to be a full, comprehensive quarterly/interim report (IR) or a formal Annual Report (10-K), nor is it a transcript (CT) or a presentation (IP), the most fitting category for an initial, high-level announcement of financial/clinical performance data is 'Earnings Release' (ER). The document length (30,967 chars) is substantial, suggesting more than just a brief notification, but the content is focused on results dissemination, not comprehensive financial reporting. Q1 2016
2016-03-24 English
UCB Exxelerate Cimzia Press Release FR
Legal Proceedings Report Classification · 99% confidence The document is a press release from UCB announcing the results of a clinical study (EXXELERATE) comparing Cimzia® and Humira® for rheumatoid arthritis. It details efficacy data (ACR 20 response rates, low disease activity at two years), safety profiles, and study methodology. The text explicitly states it is 'INFORMATION RÉGLEMENTÉE' (Regulated Information) and discusses clinical trial outcomes, which are typically released as part of an Earnings Release (ER) or a broader Investor Presentation (IP) if it were a slide deck. Since this is a detailed announcement of new clinical data and financial/operational results (even if focused on R&D outcomes), and it is not a full annual report (10-K), a quarterly report (IR), or a transcript (CT), it best fits the category for initial financial/operational results announcements. Given the content focuses on announcing specific study results and key performance indicators (efficacy/safety), it aligns most closely with an Earnings Release (ER) which often includes significant operational updates beyond just raw numbers, or potentially an Investor Presentation (IP) if it were structured as slides. However, as a formal press release announcing key findings, ER is the most appropriate fit among the provided options for a significant operational/clinical update. It is not a DEF 14A (Remuneration), DIRS (Director's Dealing), or a simple DIV notice. It is a comprehensive announcement of results, not just a notice that a report is attached (RPA/RNS).
2016-03-24 French
UCB Exxelerate Cimzia Press Release NL
Earnings Release Classification · 99% confidence The document is written in Dutch and announces the top-line results of a comparative clinical study (EXXELERATE) for the drug Cimzia® against Humira® in rheumatoid arthritis patients. It details primary endpoints (ACR20 response, low disease activity), safety profiles, and future plans to submit data for presentation at conferences and peer-reviewed journals. This content structure—announcing specific clinical trial results, quoting key personnel (Head of Immunology, Chief Medical Officer), and providing detailed study methodology (Over Exxelerate section)—is characteristic of a press release or an announcement of new scientific findings. Since it is an announcement of results rather than the full, comprehensive annual filing (10-K) or a quarterly report (IR), and it is not a transcript (CT) or a general regulatory filing (RNS), the most appropriate category is 'Earnings Release' (ER) if it were quarterly results, but since this is a specific clinical data announcement, it often falls under a general announcement category. However, given the options, this is a specific announcement of company/product news that is not a standard financial report, dividend notice, or management change. It is a detailed announcement of clinical data, which often accompanies or precedes an Earnings Release, but is distinct. Since it is a formal announcement of results, and not a short notice about a report being available (RPA), it is best classified as an 'Earnings Release' (ER) if we interpret 'Earnings' broadly as 'Periodical Results Announcement', or 'Regulatory Filing' (RNS) as a fallback. Given the context of financial reporting databases, detailed clinical trial result announcements are often grouped with ERs or treated as specific news releases. Since it is a major announcement of study results, and not a standard financial report, 'ER' is plausible if it's tied to a reporting period, but 'RNS' (Regulatory Filings/General Announcement) is a safer fit for non-standard, specific corporate news releases that aren't explicitly defined elsewhere. Given the depth of the announcement, it functions like a major news release. I will lean towards 'ER' as it announces 'results' (albeit clinical, not financial earnings), but 'RNS' is also a strong candidate. Since it is a major announcement of study results, which often drives investor sentiment similar to an ER, I will select ER, noting the ambiguity. Re-evaluating: It is a press release announcing clinical trial results, not financial earnings. Therefore, 'RNS' (Regulatory Filings/General Announcement) is the most appropriate catch-all for specific, non-financial, non-management corporate announcements. Q1 2016
2016-03-24 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.